Are all cell therapies created equal?
Edward K. Geissler
Head of Experimental Surgery
Department of Surgery
University Hospital Regensburg
Regensburg, Germany
Ed Geissler is a scientist at the University of Regensburg working in different areas spanning the field of Transplantation including basic immunology and tolerance, solid organ transplantation, immunosuppressive therapies and post-transplant malignancy. He has focussed on the understanding and prevention of immunologic rejection of transplanted organs and on novel, as well as conventional, immunosuppressive therapies to prevent transplant rejection. He also has an interest in post-transplant development of cancer, and has made a strong translational research effort through molecular targeting to reduce the threat of malignancies in transplant recipients. In another effort to reduce the burden of immunosuppressive drugs, he is leading an initiative to introduce cellular therapy in transplant recipients. Transfer of new ideas from the basic research lab to the transplant recipient is a central theme of his work.
The promise of IL-2 therapy in transplantation
Alberto Sanchez Fueyo
Professor of Hepatology, Department of Inflammation Biology
Academic Director of the Institute of Liver Studies
King’s College London
London, UK
Prof. Sánchez-Fueyo received his MD from the University of Barcelona in 1993 and trained in Gastroenterology & Hepatology at Hospital Clinic Barcelona. He conducted post-doctoral research in Transplant Immunology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston, USA) and was a faculty member at the Liver Transplant Unit at the Hospital Clinic Barcelona/IDIBAPS (University of Barcelona), where he directed the Liver Transplant Immunology Lab from 2004 to 2012. Prof. A. Sánchez-Fueyo joined King’s College London as Head of the Liver Sciences Department in 2012. His research is focused on understanding the mechanisms responsible for immunological tolerance in transplantation and developing novel immunotherapies in liver diseases.
